NCT00483938View on ClinicalTrials.gov

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

PHASE3CompletedINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Pegylated-interferon Alfa-2a

Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.

DRUG

Ribavirin

Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.

Trial Locations (23)

53210

Milwaukee

T2N 4Z6

Calgary

T5H 4B9

Edmonton

T6G 2X8

Edmonton

V2S 3N5

Abbotsford

V5Z 1M9

Vancouver

V6Z 2K5

Vancouver

V1T 1W9

Vernon

V8V 3P9

Victoria

B3H 2Y9

Halifax

M4C 3E7

East York

L8L 2X2

Hamilton

K7L 5G2

Kingston

N6A 5A5

London

L5M 4N4

Mississauga

K1H 8L6

Ottawa

M5G 1L7

Toronto

M5G 1X5

Toronto

M6H 3M1

Toronto

L4L 4Y7

Woodbridge

H1T 2M4

Montreal

H3A 1A1

Montreal

S7N 0W8

Saskatoon

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00483938 - The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) | Biotech Hunter | Biotech Hunter